Welcome to our dedicated page for AINOS news (Ticker: AIMDW), a resource for investors and traders seeking the latest updates and insights on AINOS stock.
Ainos Inc (AIMDW) is a biotechnology innovator merging AI-driven diagnostics with novel interferon therapeutics. This page provides centralized access to official announcements, clinical trial updates, and strategic developments across its human and animal health divisions.
Investors and industry stakeholders will find timely updates on VELDONA therapeutic progress, AI Nose technology deployments, and regulatory milestones. Content spans earnings reports, partnership announcements, product launch details, and peer-reviewed research findings.
Key focus areas include advancements in low-dose oral interferon formulations for rare disease treatment and AI-powered VOC detection systems for telehealth applications. All materials adhere to factual reporting standards, ensuring reliable tracking of the company’s dual therapeutic and diagnostic pipelines.
Bookmark this page for streamlined monitoring of Ainos’ innovations in AI-driven healthcare solutions and biotechnology commercialization efforts.
Ainos (NASDAQ:AIMD) has successfully integrated its AI Nose technology into a humanoid robot developed by ugo, Japan's leading service robot company, according to a new Water Tower Research report. The integration was completed within weeks of announcing the partnership, marking a global first in robotic smell detection.
The project is now entering the software integration phase, with backend control system and user interface design expected to complete in 2-4 weeks. Field testing will follow in various environments including office buildings, data centers, manufacturing plants, and public facilities.
The partnership targets Japan's robust robotics market, which produced 38% of global robots in 2023 and has a projected service robot market of $1.2 billion in 2025. The global service robotics market is estimated at $40.6 billion. Ainos plans a pilot launch in 2025 followed by commercial rollout in 2026, utilizing a subscription-based revenue model.
Ainos (NASDAQ:AIMD) has achieved a groundbreaking milestone by successfully installing its AI Nose olfaction module on a humanoid robot developed by ugo, Japan's leading service robotics company, marking the world's first robot with a functional sense of smell.
The installation, completed on April 9, 2025, integrates Ainos' proprietary system combining gas sensor arrays, real-time processing, and AI algorithms to digitize and identify volatile organic compounds into 'Smell IDs'. This technology enables robots to detect odors and environmental conditions similar to human olfaction.
Following the installation, the companies will proceed with software integration and real-world training, expected to complete within 2-4 weeks. The system will then undergo deployment tests in commercial buildings and public spaces, focusing on odor detection, safety alerts, and data collection for AI model training.
Applications include:
- Smart manufacturing for gas leak and chemical anomaly detection
- Workplace safety monitoring
- Healthcare and elderly care surveillance
- Consumer applications in smart homes and food freshness
Ainos (NASDAQ:AIMD) has achieved significant milestones in advancing its VELDONA® oral interferon drug platform. The company secured TFDA approval for HIV-related oral warts clinical trial and IRB clearance for Sjögren's Syndrome study in Taiwan.
The HIV oral warts trial (Protocol ID: 03HUHI19) will commence in June 2025 at National Taiwan University Hospital, targeting completion in 2H 2026. The global market for HIV-related HPV manifestations is estimated at $500-700 million.
The Sjögren's Syndrome trial (Protocol ID: 24PSS01) received IRB approval from Taipei Medical University, with TFDA clearance expected in August 2025. The trial aims to evaluate VELDONA's efficacy in improving salivary flow and alleviating dryness symptoms, targeting completion in 1H 2027. The global Sjögren's Syndrome therapeutics market is projected to reach $3.3 billion by 2030.
Ainos (NASDAQ:AIMD) is expanding its AI Nose technology from healthcare into robotics and semiconductor manufacturing, according to a new Water Tower Research report. The company's proprietary technology digitizes scent into Smell IDs using MEMS sensors and AI models, achieving nearly 80% accuracy across 22 VOC types in semiconductor settings and over 90% accuracy in women's health applications.
The company has secured strategic partnerships in Japan with a service robot company for integration into robots operating in office buildings, data centers, and public infrastructure. Additionally, Ainos is collaborating with the world's largest semiconductor packaging and testing company for smart factory initiatives.
The company's execution timeline includes: mass production of elderly care products in 1H 2025, pilot deployment in robotics and semiconductor factories in 2H 2025, and industrial projects scaling commercially in 2026. These initiatives target the e-nose market, projected to reach $76.5B by 2032, and the robotics market, expected to reach $178.6B by 2030.
Ainos (NASDAQ:AIMD), a pioneer in AI-powered scent digitization, has announced its participation in an upcoming fireside chat with Water Tower Research (WTR) scheduled for April 8, 2025, at 10:00 a.m. ET.
The discussion will feature WTR's senior research analyst Do Kim and managing director John Roy. During the session, Ainos will explore various aspects of their AI Nose technology, including:
- Applications in smart manufacturing and robotics
- Impact of AI-driven digitized smell beyond healthcare
- Recent collaboration programs in robotic and semiconductor manufacturing
- Technological advancements in training AI's digital olfaction
- Market opportunities across different industries
The event will be listen-only, with a replay available on Ainos' investor relations website.
Ainos (NASDAQ:AIMD) has formed a strategic partnership with Advanced Semiconductor Engineering (ASE), the world's largest semiconductor packaging and testing services provider, as highlighted in a new Water Tower Research report. The collaboration will integrate Ainos' AI Nose technology into ASE's factories.
The AI-powered electric nose technology has previously demonstrated nearly 80% accuracy in detecting 22 VOCs in Japanese semiconductor facilities. This partnership follows Ainos' recent collaboration with ugo, Inc. to create the first robots with smell capabilities.
ASE, operating under ASE Technology Holding Co. with a $21 billion market cap and $19 billion in FY24 revenue, runs 46 lights-out factories and employs over 700 automation engineers. The partnership will initially focus on optimizing AI Nose for semiconductor packaging and testing environments, followed by plans for large-scale deployment within ASE facilities and exploration of broader industrial applications.
Ainos (NASDAQ:AIMD) has announced a strategic partnership with Advanced Semiconductor Engineering (ASE) to implement AI-powered scent digitization in semiconductor manufacturing. The collaboration will integrate Ainos' patented AI Nose technology, which analyzes airborne chemicals into 'Smell IDs', into ASE's smart factories.
The AI Nose technology has demonstrated nearly 80% accuracy in identifying 22 different VOCs in Japanese semiconductor facilities. The system will enable real-time air quality monitoring, predictive maintenance, process optimization, and enhanced ESG compliance across ASE's 46 fully automated factories.
Under a legally binding MOU, the partnership aims to:
- Refine VOC detection for semiconductor environments
- Plan large-scale AI Nose deployment across ASE operations
- Explore broader industrial applications
Ainos (NASDAQ:AIMD) reported its fiscal year 2024 financial results, marking a transition from COVID-19 testing to advancing VELDONA® and AI Nose programs. The company's AI Nose program achieved up to 94% accuracy in clinical trials for women's health testing, while its VOC detection platform showed 80% accuracy in semiconductor applications.
Financial highlights include:
- Revenue declined to $20,729 in 2024 from $122,112 in 2023
- Net loss increased to $14.86M from $13.77M in 2023
- Cash position improved to $3.89M from $1.89M year-over-year
- R&D expenses rose to $8.41M from $7.32M
- SG&A expenses decreased to $5.40M from $5.64M
Key developments include a partnership with Taiwan Tanabe Seiyaku for VELDONA® manufacturing and IRB approval for Sjögren's syndrome clinical trials. The company plans to commence second-generation Ainos Flora clinical studies in H1 2025 and aims to submit IND applications to the FDA by H2 2025.
Ainos (NASDAQ:AIMD) has formed a strategic partnership with ugo Inc., a leading Japanese service robotics company, to integrate AI Nose technology into service robots. The collaboration, highlighted in a Water Tower Research report, marks a breakthrough in digitizing olfactory sensing.
The partnership aims to enhance robotic capabilities across industrial safety, public security, environmental monitoring, and healthcare. ugo, which leads Japan's service robot market share, deploys its robots in commercial buildings, data centers, factories, and public facilities.
The integration represents a significant advancement in robotics, adding smell capability to existing features like collision detection, AI-powered image recognition, and environmental sensing. Commercial deployment is expected by 2026, targeting the Japanese market, which accounts for 38% of worldwide robot production. The service robot market in Japan is projected to reach $1.2 billion by 2025, part of a $40.6 billion global market.
Ainos (NASDAQ:AIMD) has secured a significant Japanese patent (No. 7619659) for VELDONA®, its innovative oral interferon formulation designed to treat and prevent coronavirus infections. This follows a recent patent approval in Taiwan, strengthening the company's global IP portfolio in a market projected to exceed $16 billion by 2031.
The patent includes 15 key claims covering VELDONA's formulation, featuring low-dose administration under 1,000 IU, sublingual and buccal delivery mechanisms, and flexible dosage forms. Unlike traditional interferon therapies, VELDONA® doesn't require cold chain logistics, significantly reducing costs.
The technology offers dual benefits for coronavirus treatment and prevention, with proven broad-spectrum antiviral efficacy against multiple variants. VELDONA® addresses accessibility through non-invasive oral therapy, affordability by eliminating cold chain dependency, and enhanced safety through its low-dose formulation.
